MedKoo Cat#: 535102 | Name: KVA-D-88
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KVA-D-88 is an inhibitor of phosphodiesterase 4B (PDE4B). It is selective for PDE4B over a panel of 20 PDE isoforms and a panel of 39 CNS receptors at 10 µM but does inhibit the activity of PDE4C1, PDE3B, the serotonin receptor subtype 5-HT2C, and sigma-2 (σ2) receptors by greater than 50%. KVA-D-88 decreases LPS- or Pam3Cys-induced production of TNF-α in mouse bone marrow-derived macrophages. It reduces cocaine self-administration and the progressive ratio breakpoint in mice when administered at a dose of 5 mg/kg.

Chemical Structure

KVA-D-88
KVA-D-88
CAS#2410550-31-9

Theoretical Analysis

MedKoo Cat#: 535102

Name: KVA-D-88

CAS#: 2410550-31-9

Chemical Formula: C17H11Cl2F2N3O

Exact Mass: 381.0247

Molecular Weight: 382.19

Elemental Analysis: C, 53.43; H, 2.90; Cl, 18.55; F, 9.94; N, 10.99; O, 4.19

Price and Availability

Size Price Availability Quantity
1mg USD 250.00 2 Weeks
5mg USD 550.00 2 Weeks
10mg USD 950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
KVA-D-88; KVA-D 88; KVA-D88; KVAD-88; KVA D-88; KVAD88; KVA D 88;
IUPAC/Chemical Name
(1-(3,4-Dichlorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)(3,3-difluoroazetidin-1-yl)methanone
InChi Key
JQEUSIGJVMRCOL-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H11Cl2F2N3O/c18-12-4-3-11(7-13(12)19)24-14(6-10-2-1-5-22-15(10)24)16(25)23-8-17(20,21)9-23/h1-7H,8-9H2
SMILES Code
O=C(C1=CC2=CC=CN=C2N1C3=CC=C(Cl)C(Cl)=C3)N4CC(F)(F)C4
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Biological target:
KVA-D-88 is an inhibitor of phosphodiesterase 4B (PDE4B).
In vitro activity:
KVA-D88 inhibited inflammatory response, promoted β-oxidation, increased the level of antioxidants in the hepatocytes, and suppressed hepatic stellate cell (HSC) activation in vitro Reference: Pharmaceutics. 2022 Sep 7;14(9):1894. https://pubmed.ncbi.nlm.nih.gov/36145643/
In vivo activity:
Pharmacokinetic studies have shown that this compound is brain penetrant and preferably acts on PDE4B compared to PDE4D in vitro, alluding to less unwanted side effects with KVA-D-88 in vivo. Interestingly, pretreatment with KVA-D-88 significantly inhibited cocaine-induced hyperlocomotor activity. Reference: ACS Chem Neurosci. 2020 Aug 5;11(15):2231-2242. https://pubmed.ncbi.nlm.nih.gov/32609488/
Solvent mg/mL mM
Solubility
DMF 30.0 78.49
DMSO 30.0 78.49
DMSO:PBS (pH 7.2) (1:5) 0.2 0.42
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 382.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Ma J, Kumar V, Mahato RI. Nanoparticle Delivery of Novel PDE4B Inhibitor for the Treatment of Alcoholic Liver Disease. Pharmaceutics. 2022 Sep 7;14(9):1894. doi: 10.3390/pharmaceutics14091894. PMID: 36145643; PMCID: PMC9501368. 2. Burkovetskaya ME, Liu Q, Vadukoot AK, Gautam N, Alnouti Y, Kumar S, Miczek K, Buch S, Hopkins CR, Guo M. KVA-D-88, a Novel Preferable Phosphodiesterase 4B Inhibitor, Decreases Cocaine-Mediated Reward Properties in Vivo. ACS Chem Neurosci. 2020 Aug 5;11(15):2231-2242. doi: 10.1021/acschemneuro.0c00170. Epub 2020 Jul 17. PMID: 32609488; PMCID: PMC8383802.
In vitro protocol:
1. Ma J, Kumar V, Mahato RI. Nanoparticle Delivery of Novel PDE4B Inhibitor for the Treatment of Alcoholic Liver Disease. Pharmaceutics. 2022 Sep 7;14(9):1894. doi: 10.3390/pharmaceutics14091894. PMID: 36145643; PMCID: PMC9501368. 2. Burkovetskaya ME, Liu Q, Vadukoot AK, Gautam N, Alnouti Y, Kumar S, Miczek K, Buch S, Hopkins CR, Guo M. KVA-D-88, a Novel Preferable Phosphodiesterase 4B Inhibitor, Decreases Cocaine-Mediated Reward Properties in Vivo. ACS Chem Neurosci. 2020 Aug 5;11(15):2231-2242. doi: 10.1021/acschemneuro.0c00170. Epub 2020 Jul 17. PMID: 32609488; PMCID: PMC8383802.
In vivo protocol:
1. Ma J, Kumar V, Mahato RI. Nanoparticle Delivery of Novel PDE4B Inhibitor for the Treatment of Alcoholic Liver Disease. Pharmaceutics. 2022 Sep 7;14(9):1894. doi: 10.3390/pharmaceutics14091894. PMID: 36145643; PMCID: PMC9501368. 2. Burkovetskaya ME, Liu Q, Vadukoot AK, Gautam N, Alnouti Y, Kumar S, Miczek K, Buch S, Hopkins CR, Guo M. KVA-D-88, a Novel Preferable Phosphodiesterase 4B Inhibitor, Decreases Cocaine-Mediated Reward Properties in Vivo. ACS Chem Neurosci. 2020 Aug 5;11(15):2231-2242. doi: 10.1021/acschemneuro.0c00170. Epub 2020 Jul 17. PMID: 32609488; PMCID: PMC8383802.
1: Burkovetskaya ME, Liu Q, Vadukoot AK, Gautam N, Alnouti Y, Kumar S, Miczek K, Buch S, Hopkins CR, Guo M. KVA-D-88, a Novel Preferable Phosphodiesterase 4B Inhibitor, Decreases Cocaine-Mediated Reward Properties in Vivo. ACS Chem Neurosci. 2020 Jul 17. doi: 10.1021/acschemneuro.0c00170. Epub ahead of print. PMID: 32609488.